Publications for Helen Rizos
Publications for Helen Rizos
2016
Welsh, S., Rizos, H., Scolyer, R., Long, G.
(2016). Resistance to combination BRAF and
MEK inhibition in metastatic melanoma: Where
to next? European Journal of Cancer, 62, 76-85.
<a
href="http://dx.doi.org/10.1016/j.ejca.2016.04.00
5">[More Information]</a>
2015
Johnson, D., Menzies, A., Zimmer, L., Eroglu,
Z., Ye, F., Zhao, S., Rizos, H., Sucker, A.,
Scolyer, R., Gutzmer, R., Kefford, R.,
Thompson, J., Pupo, G., Long, G., et al (2015).
Acquired BRAF inhibitor resistance: A
multicenter meta-analysis of the spectrum and
frequencies, clinical behaviour, and phenotypic
associations of resistance mechanisms. European
Journal of Cancer, 51(18), 2792-2799. <a
href="http://dx.doi.org/10.1016/j.ejca.2015.08.02
2">[More Information]</a>
Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira,
M., Lo, J., Tembe, V., Freeman, J., Lee, J.,
Scolyer, R., Long, G., Carlino, M., et al (2015).
Circulating tumor DNA to monitor treatment
response and detect acquired resistance in
patients with metastatic melanoma. Oncotarget,
6(39), 42008-42018. <a
href="http://dx.doi.org/10.18632/oncotarget.578
8">[More Information]</a>
Carlino, M., Fung, C., Shahheydari, H., Todd, J.,
Boyd, S., Irvine, M., Nagrial, A., Scolyer, R.,
Kefford, R., Long, G., Rizos, H. (2015).
Pre-existing MEK1P124 mutations diminish
response to BRAF inhibitors in metastatic
melanoma patients. Clinical Cancer Research,
21(1), 98-105. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR14-0759">[More Information]</a>
Tembe, V., Martino-Echarri, E., Marzec, K.,
Mok, M., Brodie, K., Mills, K., Lei, Y., deFazio,
A., Rizos, H., Kettle, E., Henderson, B., et al
(2015). The BARD1 BRCT domain contributes
to p53 binding, cytoplasmic and mitochondrial
localization, and apoptotic function. Cellular
Signalling, 27(9), 1763-1771. <a
href="http://dx.doi.org/10.1016/j.cellsig.2015.05.
011">[More Information]</a>
2014
Rizos, H., Menzies, A., Pupo, G., Carlino, M.,
Fung, C., Hyman, J., Haydu, L., Mijatov, B.,
Becker, T., Boyd, S., Howle, J., Saw, R.,
Thompson, J., Kefford, R., Scolyer, R., Long, G.
(2014). BRAF inhibitor resistance mechanisms
in metastatic melanoma: spectrum and clinical
impact. Clinical Cancer Research, 20(7),
1965-1977. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR13-3122">[More Information]</a>
Gallagher, S., Mijatov, B., Gunatilake, D.,
Gowrishankar, K., Tiffen, J., James, W., Jin, L.,
Pupo, G., Cullinane, C., McArthur, G., Rizos, H.,
Hersey, P., et al (2014). Control of NF-kB
activity in human melanoma by bromodomain
and extra-terminal protein inhibitor I-BET151.
Pigment Cell & Melanoma Research, 27(6),
1126-1137. <a
href="http://dx.doi.org/10.1111/pcmr.12282">[
More Information]</a>
Carlino, M., Todd, J., Gowrishankar, K.,
Mijatov, B., Pupo, G., Fung, C., Snoyman, S.,
Hersey, P., Long, G., Kefford, R., Rizos, H.
(2014). Differential activity of MEK and ERK
inhibitors in BRAF inhibitor resistant melanoma.
Molecular Oncology, 8(3), 544-554. <a
href="http://dx.doi.org/10.1016/j.molonc.2014.0
1.003">[More Information]</a>
Long, G., Fung, C., Menzies, A., Pupo, G.,
Carlino, M., Hyman, J., Shahheydari, H., Tembe,
V., Thompson, J., Saw, R., Howle, J., Scolyer,
R., Kefford, R., Rizos, H., et al (2014). Increased
MAPK reactivation in early resistance to
dabrafenib/trametinib combination therapy of
BRAF-mutant metastatic melanoma. Nature
Communications, 5, 1-9. <a
href="http://dx.doi.org/10.1038/ncomms6694">[
More Information]</a>
Gopal, V., Rizos, H., Chen, G., Deng, W.,
Frederick, D., Cooper, Z., Scolyer, R., Pupo, G.,
Komurov, K., Sehgal, V., Long, G., et al (2014).
Inhibition of mTORC1/2 overcomes resistance to
MAPK pathway inhibitors mediated by PGC1α
and oxidative phosphorylation in melanoma.
Cancer Research, 74(23), 7037-7047.
Becker, T., Boyd, S., Mijatov, B., Gowrishankar,
K., Snoyman, S., Pupo, G., Scolyer, R., Mann,
G., Kefford, R., Zhang, X., Rizos, H. (2014).
Mutant B-RAF-Mcl-1 survival signaling depends
on the STAT3 transcription factor. Oncogene,
33(9), 1158-1166. <a
href="http://dx.doi.org/10.1038/onc.2013.45">[
More Information]</a>
Croft, A., Tay, K., Boyd, S., Guo, S., Jiang, C.,
Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P.,
et al (2014). Oncogenic Activation of MEK/ERK
Primes Melanoma Cells for Adaptation to
Endoplasmic Reticulum Stress. Journal of
Investigative Dermatology, 134(2), 488-497. <a
href="http://dx.doi.org/10.1038/jid.2013.325">[
More Information]</a>
Parmenter, T., Kleinschmidt, M., Kinross, K.,
Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard,
K., Hugo, W., Pupo, G., Long, G., Scolyer, R.,
Rizos, H., et al (2014). Response of
Publications for Helen Rizos
BRAF-mutant melanoma to BRAF inhibition is
mediated by a network of transcriptional
regulators of glycolysis. Cancer Discovery, 4(4),
423-433. <a
href="http://dx.doi.org/10.1158/2159-8290.CD-1
3-0440">[More Information]</a>
Inhibition Following Acquired Resistance to
BRAF and/or MEK Inhibition in Melanoma.
Molecular Cancer Therapeutics, 12(7),
1332-1342. <a
href="http://dx.doi.org/10.1158/1535-7163.MCT
-13-0011">[More Information]</a>
Cisterne, A., Baraz, R., Khan, N., Welschinger,
R., Basnett, J., Fung, C., Rizos, H., Bradstock,
K., Bendall, L. (2014). Silencer of death domains
controls cell death through tumour necrosis
factor-receptor 1 and caspase-10 in acute
lymphoblastic leukemia. PloS One, 9(7), 1-10.
<a
href="http://dx.doi.org/10.1371/journal.pone.010
3383">[More Information]</a>
Long, G., Wilmott, J., Haydu, L., Tembe, V.,
Sharma, R., Rizos, H., Thompson, J., Howle, J.,
Scolyer, R., Kefford, R. (2013). Effects of BRAF
inhibitors on human melanoma tissue before
treatment, early during treatment and on
progression. Pigment Cell & Melanoma
Research, 26(4), 499-508. <a
href="http://dx.doi.org/10.1111/pcmr.12098">[
More Information]</a>
Chien, A., Haydu, L., Biechele, T., Kulikauskas,
R., Rizos, H., Kefford, R., Scolyer, R., Moon, R.,
Long, G. (2014). Targeted BRAF Inhibition
Impacts Survival in Melanoma Patients with
High Levels of Wnt/Beta-Catenin Signaling.
PloS One, 9(4), 1-11.
Tran, S., Rizos, H. (2013). Human nevi lack
distinguishing senescence traits. Aging, 5(2),
98-99. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=23518674">[More Information]</a>
Gallagher, S., Mijatov, B., Gunatilake, D.,
Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G.,
Cullinane, C., Prinjha, R., Smithers, N., Rizos,
H., Hersey, P., et al (2014). The Epigenetic
Regulator I-BET151 Induces BIM Dependent
Apoptosis and Cell Cycle Arrest OF Human
Melanoma Cells. Journal of Investigative
Dermatology, 134(11), 2795-2805. <a
href="http://dx.doi.org/10.1038/jid.2014.243">[
More Information]</a>
Tran, S., Rizos, H. (2013). Monitoring
Oncogenic B-RAF-Induced Senescence in
Melanocytes. In Lorenzo Galluzzi, Ilio Vitale,
Oliver Kepp and Guido Kroemer (Eds.), Methods
in Molecular Biology, Cell Senescence: Methods
and Protocols, (pp. 313-326). New York:
Springer Science+Business Media.
Todd, J., Scurr, L., Becker, T., Kefford, R.,
Rizos, H. (2014). The MAPK pathway functions
as a redundant survival signal that reinforces the
PI3K cascade in c-Kit mutant melanoma.
Oncogene, 33(2), 236-245. <a
href="http://dx.doi.org/10.1038/onc.2012.562">[
More Information]</a>
Anastas, J., Kulikauskas, R., Tamir, T., Rizos,
H., Long, G., von Euw, E., Yang, P., Chen, H.,
Haydu, L., Toroni, R., et al (2014). WNT5A
enhances resistance of melanoma cells to
targeted BRAF inhibitors. Journal of Clinical
Investigation, 124(7), 2287-2890. <a
href="http://dx.doi.org/10.1172/JCI70156">[Mor
e Information]</a>
2013
Gowrishankar, K., Carlino, M., Rizos, H. (2013).
Acquired Resistance to Targeted MAPK
Inhibition in Melanoma. In Guy Huynh Thien
Duc (Eds.), Melanoma - From Early Detection to
Treatment, (pp. 197-218). Croatia: Intech.
Carlino, M., Gowrishankar, K., Saunders, C.,
Pupo, G., Snoyman, S., Zhang, X., Saw, R.,
Becker, T., Kefford, R., Long, G., Rizos, H.
(2013). Antiproliferative Effects of Continued
Mitogen-Activated Protein Kinase Pathway
Boyd, S., Mijatov, B., Pupo, G., Tran, S.,
Gowrishankar, K., Shaw, H., Goding, C.,
Scolyer, R., Mann, G., Kefford, R., Rizos, H.,
Becker, T. (2013). Oncogenic B-RAF(V600E)
Signaling Induces the T-Box3 Transcriptional
Repressor to Repress E-Cadherin and Enhance
Melanoma Cell Invasion. Journal of
Investigative Dermatology, 133(5), 1269-1277.
<a
href="http://dx.doi.org/10.1038/jid.2012.421">[
More Information]</a>
Fung, C., Pupo, G., Scolyer, R., Kefford, R.,
Rizos, H. (2013). p16INK4a deficiency promotes
DNA
hyper-replication and genetic instability in
melanocytes. Pigment Cell & Melanoma
Research, 26(2), 236-246. <a
href="http://dx.doi.org/10.1111/pcmr.12062">[
More Information]</a>
Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B.,
Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L.,
Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2
5-phosphatase A regulates PI3K/Akt signalling
and has a tumour suppressive role in human
melanoma. Nature Communications, 4, 1-15. <a
href="http://dx.doi.org/10.1038/ncomms2489">[
More Information]</a>
Todd, J., Becker, T., Kefford, R., Rizos, H.
(2013). Secondary c-Kit mutations confer
Publications for Helen Rizos
acquired resistance to RTK inhibitors in c-Kit
mutant melanoma cells. Pigment Cell &
Melanoma Research, 26(4), 518-526. <a
href="http://dx.doi.org/10.1111/pcmr.12107">[
More Information]</a>
2012
Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S.,
Rahme, R., Wang, B., Rua, R., Rizos, H.,
Carroll, A., Saksena, N., et al (2012). A parallel
genome-wide mRNA and microRNA profiling of
the frontal cortex of HIV patients with and
without HIV-associated dementia shows the role
of axon guidance and downstream pathways in
HIV-mediated neurodegeneration. BMC
Genomics, 13(November), 1-17. <a
href="http://dx.doi.org/10.1186/1471-2164-13-6
77">[More Information]</a>
Tran, S., Haferkamp, S., Scurr, L.,
Gowrishankar, K., Becker, T., Desilva, C.,
Thompson, J., Scolyer, R., Kefford, R., Rizos, H.
(2012). Absence of Distinguishing Senescence
Traits in Human Melanocytic Nevi. Journal of
Investigative Dermatology, 132(9), 2226-2234.
<a
href="http://dx.doi.org/10.1038/jid.2012.126">[
More Information]</a>
Gowrishankar, K., Snoyman, S., Pupo, G.,
Becker, T., Kefford, R., Rizos, H. (2012).
Acquired Resistance to BRAF Inhibition Can
Confer Cross-Resistance to Combined
BRAF/MEK Inhibition. Journal of Investigative
Dermatology, 132(7), 1850-1859. <a
href="http://dx.doi.org/10.1038/jid.2012.63">[M
ore Information]</a>
Wilmott, J., Tembe, V., Howle, J., Sharma, R.,
Thompson, J., Rizos, H., Lo, R., Kefford, R.,
Scolyer, R., Long, G. (2012). Intratumoral
Molecular Heterogeneity in a BRAF-Mutant,
BRAF Inhibitor-Resistant Melanoma: A Case
Illustrating the Challenges for Personalized
Medicine. Molecular Cancer Therapeutics,
11(12), 2704-2708. <a
href="http://dx.doi.org/10.1158/1535-7163.MCT
-12-0530">[More Information]</a>
David, M., Huynh, M., Kelly, E., Rizos, H.,
Coleman, H., Rogers, G., Zoellner, H. (2012).
Membrane and cytoplasmic marker exchange
between malignant neoplastic cells and
fibroblasts via intermittent contact: increased
tumour cell diversity independent of genetic
change. Journal of Pathology, 228(4), 495-505.
<a
href="http://dx.doi.org/10.1002/path.4063">[Mo
re Information]</a>
Scurr, L., McKenzie, H., Becker, T., Irvine, M.,
Lai, K., Mann, G., Scolyer, R., Kefford, R.,
Rizos, H. (2012). Selective Loss of Wild-Type
p16(INK4a) Expression in Human Nevi. Journal
of Investigative Dermatology, 131(11),
2329-2332. <a
href="http://dx.doi.org/10.1038/jid.2011.197">[
More Information]</a>
2011
Medic, S., Rizos, H., Ziman, M. (2011).
Differential PAX3 functions in normal skin
melanocytes and melanoma cells. Biochemical
and Biophysical Research Communications,
411(4), 832-837. <a
href="http://dx.doi.org/10.1016/j.bbrc.2011.07.0
53">[More Information]</a>
Avery-Kiejda, K., Bowden, N., Croft, A., Scurr,
L., Kairupan, C., Ashton, K., Talseth-Palmer, B.,
Rizos, H., Zhang, X., Scott, R., et al (2011). P53
in human melanoma fails to regulate target genes
associated with apoptosis and the cell cycle and
may contribute to proliferation. BMC Cancer,
11(203), 1-17. <a
href="http://dx.doi.org/10.1186/1471-2407-11-2
03">[More Information]</a>
Rizos, H., Scurr, L. (2011). Senescence. In
Anja Bosserhoff (Eds.), Melanoma
Development: Molecular Biology, Genetics and
Clinical Application, (pp. 235-254). Vienna:
Springer.
2010
Irvine, M., Boyd, S., Frausto, M., Mijatov, B.,
Gallagher, S., Fung, C., Becker, T., Kefford, R.,
Rizos, H. (2010). Amino terminal hydrophobic
import signals target the p14(ARF) tumor
suppressor to the mitochondria. Cell Cycle, 9(4),
829-839. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=20107316">[More Information]</a>
Jiang, C., Lai, F., Tay, K., Croft, A., Rizos, H.,
Becker, T., Yang, F., Liu, H., Thorne, R.,
Hersey, P., et al (2010). Apoptosis of Human
Melanoma Cells Induced by Inhibition of
B-RAFV600E Involves Preferential Splicing of
BimS. Cell Death and Disease, 1(9),
e69-1-e69-14. <a
href="http://dx.doi.org/10.1038/cddis.2010.48">[
More Information]</a>
Zhou, L., Diefenbach, E., Crossett, B., Tran, S.,
Ng, T., Rizos, H., Rua, R., Wang, B., Kapur, A.,
Gandhi, K., Saksena, N., et al (2010). First
evidence of overlaps between HIV-Associated
Dementia (HAD) and non-viral
neurodegenerative diseases: proteomic analysis
of the frontal cortex from HIV+ patients with and
without dementia. Molecular
Neurodegeneration, 5(27), 27-1-27-20. <a
href="http://dx.doi.org/10.1186/1750-1326-5-27"
>[More Information]</a>
Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama,
Publications for Helen Rizos
D., Haferkamp, S., Irvine, M., Scolyer, R.,
Mann, G., Becker, J., Kefford, R., Rizos, H.
(2010). IGFBP7 Is Not Required for
B-RAF-Induced Melanocyte Senescence. Cell,
141(4), 717-727. <a
href="http://dx.doi.org/10.1016/j.cell.2010.04.02
1">[More Information]</a>
Boyd, S., Scurr, L., Fung, C., Haferkamp, S.,
Kefford, R., Rizos, H. (2010). Oncogenic
B-RAF(V600E) Promotes
Anchorage-Independent Survival of Human
Melanocytes. Journal of Investigative
Dermatology, 130(8), 2144-7. <a
href="http://dx.doi.org/10.1038/jid.2010.117">[
More Information]</a>
McKenzie, H., Fung, C., Becker, T., Irvine, M.,
Mann, G., Kefford, R., Rizos, H. (2010).
Predicting functional significance of
cancer-associated p16(INK4a) mutations in
CDKN2A. Human Mutation, 31(6), 692-701. <a
href="http://dx.doi.org/10.1002/humu.21245">[
More Information]</a>
2009
Haferkamp, S., Scurr, L., Becker, T., Frausto,
M., Kefford, R., Rizos, H. (2009).
Oncogene-Induced Senescence Does Not
Require the p16INK4a or p14ARF Melanoma
Tumor Suppressors. Journal of Investigative
Dermatology, 129(8), 1983-1991. <a
href="http://dx.doi.org/10.1038/jid.2009.5">[Mo
re Information]</a>
Becker, T., Haferkamp, S., Dijkstra, M., Scurr,
L., Frausto, M., Diefenbach, E., Scolyer, R.,
Reisman, D., Mann, G., Kefford, R., Rizos, H.
(2009). The chromatin remodelling factor BRG1
is a novel binding partner of the tumor
suppressor p16INK4a. Molecular Cancer, 8(4),
4-1-4-12. <a
href="http://dx.doi.org/10.1186/1476-4598-8-4"
>[More Information]</a>
Haferkamp, S., Tran, S., Becker, T., Scurr, L.,
Kefford, R., Rizos, H. (2009). The relative
contributions of the p53 and pRb pathways in
oncogene-induced melanocyte senescence.
Aging, 1(6), 542-556. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=20157537">[More Information]</a>
McKenzie, H., Scurr, L., Kefford, R., Rizos, H.
(2009). Wild type and melanoma-associated
mutant p16(IN4a) proteins do not oligomerize in
vivo. Pigment Cell & Melanoma Research,
22(1), 131-133. <a
href="http://dx.doi.org/10.1111/j.1755-148X.200
8.00530.x">[More Information]</a>
2008
Scurr, L., Guminski, A., Chiew, Y., Balleine, R.,
Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand,
A., Byth, K., Kennedy, C., Rizos, H., Harnett, P.,
deFazio, A. (2008). Ankyrin Repeat Domain 1,
ANKRD1, a Novel Determinant of Cisplatin
Sensitivity Expressed in Ovarian Cancer.
Clinical Cancer Research, 14(21), 6924-6932.
<a
href="http://dx.doi.org/10.1158/1078-0432.CCR07-5189">[More Information]</a>
Haferkamp, S., Becker, T., Scurr, L., Kefford,
R., Rizos, H. (2008). p16(INK4a)-induced
senescence is disabled by melanoma-associated
mutations. Aging Cell, 7(5), 733-745. <a
href="http://dx.doi.org/10.1111/j.1474-9726.200
8.00422.x">[More Information]</a>
Gallagher, S., Thompson, J., Indsto, J., Scurr, L.,
Lett, M., Gao, B., Dunleavey, R., Mann, G.,
Kefford, R., Rizos, H. (2008). p16INK4a
expression and absence of activated B-RAF are
independent predictors of chemosensitivity in
melanoma tumors. NeoPlasia: an international
journal of oncology research, 10(11),
1231-1239. <a
href="http://dx.doi.org/10.1593/neo.08702">[Mo
re Information]</a>
2007
Packer, L., Pavey, S., Boyle, G., Stark, M.,
Ayub, A., Rizos, H., Hayward, N. (2007). Gene
expression profiling in melanoma identifies
novel downstream effectors of p14ARF.
International Journal of Cancer, 121(4),
784-790. <a
href="http://dx.doi.org/10.1002/ijc.22725">[Mor
e Information]</a>
Rizos, H., Scurr, L., Irvine, M., Alling, N.,
Kefford, R. (2007). p14ARF Regulates E2F-1
Ubiquitination and Degradation via a
p53-Dependent Mechanism. Cell Cycle, 6(14),
1741-1747. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17630509">[More Information]</a>
2006
Rizos, H., McKenzie, H., Ayub, A., Woodruff,
S., Becker, T., Scurr, L., Stahl, J., Kefford, R.
(2006). Physical and functional interaction of the
p14ARF tumor suppressor with ribosomes.
Journal of Biological Chemistry, 281(49),
38080-38088. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17035234">[More Information]</a>
Gallagher, S., Kefford, R., Rizos, H. (2006). The
ARF tumour suppressor. The International
Journal of Biochemistry and Cell Biology,
38(10), 1637-1641. <a
href="http://dx.doi.org/10.1016/j.biocel.2006.02.
Publications for Helen Rizos
008">[More Information]</a>
2005
Gallagher, S., Kefford, R., Rizos, H. (2005).
Enforced expression of p14ARF induces
p53-dependent cell cycle arrest but not apoptosis.
Cell Cycle, 4(3), 465-472. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15701968">[More Information]</a>
Becker, T., Rizos, H., Dela Pena, A., Leclercq, I.,
Woodruff, S., Kefford, R., Mann, G. (2005).
Impaired inhibition of NF-kappaB activity by
melanoma-associated p16INK4a mutations.
Biochemical and Biophysical Research
Communications, 332(3), 873-879. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15913553">[More Information]</a>
Rizos, H., Woodruff, S., Kefford, R. (2005).
p14ARF interacts with the SUMO-conjugating
enzyme Ubc9 and promotes the Sumoylation of
its binding partners. Cell Cycle, 4(4), 597-603.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15876874">[More Information]</a>
Becker, T., Ayub, A., Kefford, R., Mann, G.,
Rizos, H. (2005). The melanoma-associated 24
base pair duplication in p16INK4a is functionally
impaired. International Journal of Cancer,
117(4), 569-573. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15945100">[More Information]</a>
2003
Rizos, H., Diefenbach, E., Badhwar, P.,
Woodruff, S., Becker, T., Kefford, R., Rooney,
R. (2003). Association of p14ARF with the
p120E4F transciptional represssor enhances cell
cycle inhibition. Journal of Biological
Chemistry, 278(7), 4981-4989.
2002
Rizos, H., Diefenbach, E., Badhwar, P.,
Woodruff, S., Becker, T., Rooney, R., Kefford,
R. (2002). Association of p14ARF with the
p120E4F Transcriptional Repressor Enhances
Cell Cycle Inhibition. Journal of Biological
Chemistry, 278(7), 4981-4989.
2001
Rizos, H., Puig, S., Badenas,, C., Malvehy, J.,
Darmanian, A., Jimenez, L., Mila,, M., Kefford,
R. (2001). A melanoma-associated germline
mutation in exon 1B inactivates p14ARF.
Oncogene, 20(39), 5543-5547.
Becker, T., Rizos, H., Kefford, R., Mann, G.
(2001). Functional Impairment of
Melanoma-associated p16 INK4a mutants in
melanoma cells despite retention of
cyclin-dependent kinase 4 binding1. Clinical
Cancer Research, 7, 3282-3288.
Rizos, H., Darmanian, A., Mann, G., Kefford, R.,
Holland, E. (2001). Mutations in the INK4a/ARF
Melanoma Susceptibility locus functionally
impair p14ARF. Journal of Biological
Chemistry, 276(44), 41424-41434.
2000
Rizos, H., Darmanian, A., Mann, G., Kefford, R.
(2000). Two arginine rich domains in the
p14ARF tumour suppressor mediate nucleolar
localization. Oncogene, 19(26), 2978-2985.